The aim of the study was to examine the immunohistochemical expression of a cell-cycle-related factor (p16) in order to elucidate its role in the growth and diffusion of odontogenic tumors.
Study design
Thirty-six odontogenic tumors were divided into two groups according to their clinical behavior: group A and group B composed of tumors at low and high risk of recurrences, respectively. The ANOVA test was used to detect differences between the two groups.
Results
p16 was expressed in both groups, but with different localization. A statistically significant difference was found in p16 expression of peripheral cells, with an increase in the expression in group B compared to group A (P <0.05). In addition, there was no significant difference in p16 positive expression of the central cells of odontogenic tumors, which was high in both groups.
Conclusions
The present data show a correlation between p16 expression and the biological behavior of odontogenic tumors.
KawamataN., MorosettiR., MillerC.W., ParkD., SpirinK.S., NakamakiT., TakeuchiS., HattaY., SimpsonJ., WilczynskiS., LeeY.Y., BartramC.R., KoefflerH.P.: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res, 55: 2266–2269, 1995.
3.
SerranoM., HannonG.J., BeachD.: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366: 704–707, 1993.
4.
XiongY., HannonG.J., ZhangH., CassoD., KobayashiR.: Beach, p21 is a universal inhibitor of cyclin kinases. Nature, 366: 701–704, 1993.
5.
HuangL., GoodrowT.L., ZhangS.Y., Klein-SzantoA.J., ChangH., RuggeriB.A.: Deletion and mutation analyses of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res, 56: 1137–1141, 1996.
6.
KambA., GruisN.A., Weaver-FeldhausJ., LiuQ., HarshmanK., TavtigianS.V., StockertE., DayR.S., JohnsonB.E., SkolnickM.H.: A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264: 436–440, 1994.
7.
LermaE., EstellerM., HermanJ.G., PratJ.: Alterations of the p16INK4a/RB/ cyclin D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus. Hum Pathol, 33: 1120–1125, 2002.
8.
GranaX., ReddyE.P.: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 11: 211–219, 1995.
9.
HarperJ.W., AdamiG.R., WeiN., KeyomarsiK., ElledgeS.J.: The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805–816, 1993.
10.
PolyakK., LeeM.H., Erdjument-BromageH., KoffA., RobertsJ.M., TempstP., MassagueJ.: Cloning of p27 Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59–66, 1994.
11.
SerranoM., Gomez-LahozE., DePinhoR.A., BeachD., Bar-SagiD.: Inhibition of ras-induced proliferation and cellular transformation by p 16INK4. Science, 267: 249–252, 1995.
12.
ToyoshimaH., HunterT.: p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell, 78: 67–74, 1994.
13.
GhiorzoP., VillaggioB., SementaA.R., HanssonJ., PlatzA., NicoloG., SpinaB., CanepaM., PalmerJ.M., HaywardN.K., Bianchi-ScarraG.: Expression and localization of mutant p16 proteins in melanocytic lesions from melanoma patients. Hum Pathol, 35: 25–33, 2004.
14.
KangY.K., KimW.H., JangJ.J.: Expression of G1-S modulators (p53, p16, p27, cyclin D1, R6) and SMAD4/Dpc4 in intra-hepatic cholangiocarcinoma. Hum Pathol, 33: 877–883, 2002.
15.
RiethdorfL., RiethdorfS., LeeK.R., CvikoA., LoningT., CrumC.P.: Human papillomaviruses, expression of p16INK4A and early endocervical glandular neoplasia. Hum Pathol, 33: 899–904, 2002.
16.
HandaK., YamakawaM., TakedaH., KimuraS., TakahashiT.: Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer, 84: 225–233, 1999.
17.
HirabayashiS.: Immunohistochemical detection of DNA topoisomerase type IIa and Ki-67 in adenoid cystic carcinoma and pleomorphic adenoma of the salivary gland. J Oral Pathol Med, 28: 131–136, 1999.
18.
MaeyamaH., FuruwatariC., OtaH., AkamatsuT., NakayamaJ., KatsuyamaT.: Histone H3 messenger RNA in situ hybridization for identifying proliferating cells in formalin-fixed rat gastric mucosa. Histochem J, 29: 867–873, 1997.
19.
YabukiN., SasanoH., KatoK., OharaS., ToyotaT., NaguraH., MiyaikeM., NozakiN., KikuchiA.: Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am J Pathol, 149: 997–1007, 1996.
20.
DonnellanR., ChettyR.: Cyclin D1 and human neoplasia. Mol Pathol, 51: 1–7, 1998.
21.
JiangW., ZhangY.J., KahnS.M., HollsteinM.C., SantellaR.M., LuS.H., HarrisC.C., MontesanoR., WeinsteinI.B.: Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA, 90: 9026–9030, 1993.
22.
KudoY., TakataT., OgawaI., SatoS., NikaiH.: Expression of p53 and p21 CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas. Oncol Rep, 6: 539–545, 1999.
23.
LodaM., CukorB., TamS.W., LavinP., FiorentinoM., DraettaG.F., JessupJ.M., PaganoM.: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med, 3: 231–234, 1997.
24.
MoriyaT., SakamotoK., SasanoH., KawanakaM., SonooH., ManabeT., ItoJ.: Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases. Mod Pathol, 13: 13–18, 2000.
25.
PandeP., MathurM., ShuklaN.K., RalhanR.: pRb and p16 protein alterations in human oral tumorigenesis. Eur J Cancer B Oral Oncol, 34: 396–403, 1998.
26.
SanoT., HikinoT., XueQ., SaitoT., KashiwabaraK., OyamaT., NakajimaT.: Immuno-histochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int, 48: 580–585, 1998.
27.
ShojiM., DobashiY., MorinagaS., JiangS.X., KameyaT.: Tumor extension and cell proliferation in adenocarcinomas of the lung. Am J Pathol, 154: 909–918, 1999.
28.
van OijenM.G., TilanusM.G., MedemaR.H., SlootwegP.J.: Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression. J Oral Pathol Med, 27: 367–375, 1998.
29.
HermanJ.G., CivinC.I., IssaJ.P., CollectorM.I., SharkisS.J., BaylinS.B.: Distinct patterns of inactivation of p15 and p16 characterize the major types of haematological malignancies. Cancer Res, 57: 837–841, 1997.
30.
LiggettW.H., SidranskyD.: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol, 16: 1197–1206, 1998.
31.
KobayashiS., ShirasawaH., SashiyamaH., KawahiraH., KanekoK., AsanoT., OchiaiT.: p16 INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin Cancer Res, 5: 4182–4185, 1999.
32.
OkamotoA., DemetrickD.J., SpillareE.A., HagiwaraK., HussainS.P., BennettW.P., ForresterK., GerwinB., SerranoM., BeachD.H., HarrisC.C.: Mutations and altered expression of p16 INK4 in human cancer. Proc Natl Acad Sci USA, 91: 11045–11049, 1994.
33.
KumamotoH., KimiK., OoyaH.: Detection of cell cycle-related factors in ameloblastomas. J Oral Pathol Med, 30: 309–315, 2001.
34.
SchreiberM., MullerW.J., SinghG., GrahamF.L.: Comparison of the effectiveness of adenovirus vectors expressing cyclinkinase inhibitors p16 INK4a, p18 INK4c, p19 INK4d, p21 WAF1/CIP1 and p27 KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene, 18: 1663–1676, 1999.
35.
HallM., PetersG.: Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. Adv Cancer Res, 68: 67–108, 1996.
36.
HunterT., PinesJ.: Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell, 79: 573–582, 1994.
37.
BarnesL., EvesonJ.W., ReichartP., SidranskyD (Eds): Head and Neck Tumours, Pathology and Genetics, WHO Classification of Tumours.IARC Press, Lyon, 2005.
38.
MerloA., HermanJ.G., MaoL., LeeD.J., GabrielsonE., BurgerP.C., BaylinS.B., SidranskyD.: 5’ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med, 1: 686–692, 1995.
39.
NoboriT., MiuraK., WuD.J., LoisA., TakabayashiK., CarsonD.A.: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers, Nature, 368: 753–756, 1994.
40.
OkamotoA., HussainS.P., HagiwaraK., SpillareE.A., RusinM.R., DemetrickD.J., SerranoM., HannonG.J., ShisekiM., ZariwalaM.: Mutations in the p16INK4/ MTS1/CDKN2, p15INK4B/ MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res, 55: 1448–1451, 1995.
41.
ShintaniS., MiharaM., NakaharaY.: Infrequent alterations of RB pathway (Rb-p16 INK4A-cyclin D1) in adenoid cystic carcinoma of salivary glands. Anticancer Res, 20: 2169–2175, 2000.
42.
ReedA.L., CalifanoJ., CairnsP., WeatraW.H., JonesR.M., KochW., AhrendtS., EbyY., SewellD., NawrozH., BartekJ., SidranskyD.: High frequency of p16 inactivation in head and neck squamous cell carcinoma. Cancer Res, 56: 3630–3633, 1996.
43.
YuenP., ManM., Yin LamK., Lam KwongY.: Clinicopathologic significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinoma. J Clin Pathol, 55: 58–60, 2002.
44.
LangJ.C., BorchersJ., DanaheyD., SmithS., StoverD.G., AgrawalA., MaloneJ.P., SchullerD.E., WeghorstC.M., HolingaA.J., LingamK., PatelC.R., EshamB.: Mutational status or overex-pressed p16 in head and neck cancer: evidence for germline mutation of p16/p14 ARF. Int J Oncol, 21: 401–408, 2002.
45.
NatarajanE., SaebM., CrumC.P., WooS.B., McKeeP.H., RheinwaldJ.G.: Co-expression of p16 (INK4A) and laminin 5 gamma 2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol, 163: 477–491, 2003.
46.
ChenQ., LuoG., LiB., SamaranayakeL.P.: Expression of p16 and CDK4 in oral premalignant lesions and oral squamous cell carcinomas: a semiquantitative immunohistochemical study. J Oral Pathol Med,28: 158–164, 1999.
